JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

36.1 -0.17

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

35.36

Massimo

36.45

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+44.41% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	398M 6B
Apertura precedente	36.27
Chiusura precedente	36.1

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 apr 2026, 23:33 UTC

Utili

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 apr 2026, 22:40 UTC

Utili

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 apr 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:11 UTC

Utili

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 apr 2026, 21:01 UTC

Utili

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 apr 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 apr 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 apr 2026, 23:34 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 apr 2026, 23:16 UTC

Utili

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 apr 2026, 23:15 UTC

Utili

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 apr 2026, 22:54 UTC

Utili

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 apr 2026, 22:54 UTC

Utili

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 apr 2026, 22:52 UTC

Utili

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 apr 2026, 22:51 UTC

Utili

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 apr 2026, 22:31 UTC

Utili

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 apr 2026, 22:31 UTC

Utili

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 apr 2026, 22:30 UTC

Utili

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 apr 2026, 22:30 UTC

Utili

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 apr 2026, 22:29 UTC

Utili

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 apr 2026, 22:28 UTC

Utili

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 apr 2026, 22:28 UTC

Utili

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 apr 2026, 22:27 UTC

Utili

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 apr 2026, 22:06 UTC

Discorsi di Mercato

Utili

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 apr 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 apr 2026, 21:47 UTC

Utili

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:37 UTC

Utili

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 apr 2026, 21:34 UTC

Utili

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 apr 2026, 21:29 UTC

Utili

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 apr 2026, 21:20 UTC

Discorsi di Mercato

Utili

Tesla Expands Manufacturing to Chips -- Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.41% in crescita

Previsioni per 12 mesi

Media 52.55 USD 44.41%

Alto 64 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.